Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 24, 2025Clinical journal of oncology nursingOpen Access

Gene Therapy for Sickle Cell Disease: No Donor, No Problem

View Full Paper
Ask AI
Bookmark
Share

Authors

ESElana Smilow

Discussion

Loading...

Member takes

Overview

Gene therapy demonstrates potential for curative treatment in sickle cell disease, suggesting wider accessibility for patients.

Key Points

  • Gene therapy provides a transformative option for sickle cell disease, expanding treatment access for patients without donors.
  • Autologous gene therapy was approved by the FDA in December 2023, emphasizing its novel approach to treating this genetic disorder.
  • Supportive care for gene therapy mirrors approaches used in stem cell transplantation, requiring a skilled healthcare team.
  • This complex treatment demands careful management of logistics and insurance authorization, indicating the need for interprofessional collaboration.

Cite This Study

Elana Smilow (2025) studied this question.

synapsesocial.com/papers/68d6d82e8b2b6861e4c3e2b4https://doi.org/10.1188/25.cjon.371-375
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Current state of gene therapy in sickle cell disease2024 · 14 citations
  2. 2The Journey of Gene Therapy in Sickle Cell Disease: How Molecular Advances Meet Clinical Care2026
  3. 3Advances in gene therapy for the treatment of sickle cell anemia2024 · 1 citations
  4. 4The New Era of Curative Therapies for Sickle Cell Disease: A Comprehensive Review of Allogeneic Transplantation and Autologous Gene Therapy2026
  5. 5Curing Sickle Cell Disease by Allogeneic Hematopoietic Stem Cell (HSC) Transplantation Toward In Vivo HSC Gene Therapy2025